Cost Analysis of Biosimilars

Biologics are complex, protein-based drugs including insulin, monoclonal antibodies to block inflammation in rheumatoid arthritis, and a range of drugs to treat cancer, multiple sclerosis, and other serious diseases. While biologics have revolutionized treatment for many conditions, they are often expensive in terms of cost per dose. The introduction of biosimilars is expected to reduce prices, albeit to a lesser degree, comparable to small-molecule generics.

  • Pharmacoeconomic Modelling of Biosimilars
  • Risk management plan (RMP) for Biosimilars
  • Cost minimal analysis
  • Cost benefit analysis
  • Cost effectiveness analysis
  • Cost utility analysis
  • Quality adjusted life years

Related Conference of Cost Analysis of Biosimilars

July 03-05, 2017

4th Annual Congress on Drug Discovery & Designing

Bangkok, Thailand
August 10-12, 2017

8th Asian Biologics and Biosimilars Congress

Beijing, China
Sep 20-21, 2017

10th Pharmacovigilance Congress

Charlotte, North Carolina, USA
September 25-26, 2017(10 Plenary Forums- 1 Event)

7th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR

Chicago, Illinois, USA
September 25-26, 2017
(10 Plenary Forums - 1Event)

6th International Conference and Exhibition on GMP, GCP & Quality Control

Chicago, Illinois, USA
October 02-04, 2017

World Congress on Antibiotics: R&D, Market

Atlanta, USA
October 16-18, 2017

12th World Pharma Congress

Budapest, Hungary
October 16-18, 2017

11th World Drug Delivery Summit

(10 Plenary Forums - 1Event)
Baltimore, Maryland, USA
October 16-17, 2017

10th International Conference and Exhibition on Biologics and Biosimilars

San Francisco, California, USA
November 09-11, 2017

4th European Biopharma Congress

Vienna, Austria
Dec 14-16, 2017

7th Global Mass Spectrometry Congress

Dubai, UAE

Cost Analysis of Biosimilars Conference Speakers

Recommended Sessions

Related Journals

Are you interested in